Shenzhen Core Medical Technologies Completes Over RMB 700 Million Series D Financing, Files for IPO as China's Largest Innovative MedTech Fundraise of 2025

Smart Medical Device Network NewsRecently, Shenzhen Core Medical Technology Co., Ltd. (hereinafter referred to as"Core Medical") announced the completion of over1Billion US dollarsDRound of financing, this round led by Loyal Valley Capital, Legend Capital, and Aramco Ventures.Prosperity7 Ventures(P7), Cornerstone Capital and well-known industry investors jointly led the investment, with Delian Capital and Lianxin Capital following up. This round of financing is currently2025The largest market-based financing in China's innovative medical device sector.

Data shows, Core Medical"Founded in2016Year8Month, headquartered in Shenzhen, focuses on the research, development, and production of high-end innovative medical device products such as mechanical circulatory assist devices (commonly known as "artificial hearts"). It has achieved a comprehensive layout in the field of implantable and interventional artificial hearts, and is committed to providing a full range of solutions for heart failure patients worldwide.

In the miniaturization of artificial hearts, the ultra-small fully magnetically levitated artificial heart independently developed by Core Medical——Corheart® 6The key performance indicators have reached the same level as international similar products, effectively enhancing the competitiveness of domestically produced artificial hearts in the international market.

At the same time, in the interventional artificial heartCorVad In product lines such as these, Core Medical has also carried out innovative R&D to achieve high flow rates within smaller interventional sizes. Its self-designed micro motor and control technology have further reduced the risk of hemolysis, enhancing product stability and long-term operational reliability.

Self2019Since the year, Core Medical's innovative achievements in the artificial heart field have been highly favored by the capital market, completing four rounds of financing consecutively over four years, with a steady development momentum.

Data shows,Corheart® 6The Implantable Left Ventricular Assist System is an ultra-small, fully magnetically levitated artificial heart designed to provide hemodynamic support for patients with advanced refractory left heart failure.

Developed independently by Shenzhen Core Medical, its blood pump has a diameter of only34Millimeters, Thickness26Millimeters, weighing approximately90Core, is a small-sized and lightweight artificial heart.

Corheart® 6The blood pump adopts a unique "linear" secondary flow channel design, which reduces the dwell time of blood in the secondary flow channel, lowers the risk of blood damage and thrombosis, and achieves excellent blood compatibility. At the same time, it also uses a unique integrated motor design to enable one set of coils to control both the rotation and suspension of the impeller, breaking through the bottlenecks of traditional radial magnetic levitation such as large volume, complex structure, and high power consumption, successfully achieving a breakthrough in the miniaturization of fully magnetically levitated artificial hearts.

2023Year6Month6Day,Corheart® 6Officially received the approval from the National Medical Products Administration (NMPA) approved for marketing, with the registration certificate number Guo Xie Zhu Zhun20233120716。NMPACorrectCorheart® 6"It has been positively evaluated: 'Simpler structure, lighter weight, smaller size, lower power consumption. In clinical applications, the surgical incision is smaller, patients recover faster, it is suitable for a wider population, and can reduce the risk of thrombosis caused by blood pump heat.'"

According to Core Medical:"In the field of implantable products, although the company's products were not approved as early as some competitors, in the high-end implantable medical device sector, technical barriers are more critical. Currently, a core implantable left ventricular assist device developed by the company..."Corheart 6Adopting axial full magnetic levitation design and control technology, it is characterized by being smaller and lighter than similar products, with the pump body weighing only90g`, Peripheral Weight`800g, but the battery life has reached33"Hours."

It is reported that the artificial heart is a representative of mechanical assist devices, used to replace or assist the heart's pumping function. According to functionality, it can be divided into ventricular assist devices (assistive artificial hearts) and total artificial hearts. Ventricular assist devices can be further categorized by their level of support into left ventricular assist, right ventricular assist, and biventricular assist devices, and by duration of support into temporary assist (short-term assist) and permanent assist. Total artificial hearts also come in two types: temporary total artificial hearts, mainly used to provide temporary support while waiting for a heart transplant, and permanent total artificial hearts.

According to statistics,2023In 2023, heart transplants in China saw an increase in both "quantity and quality," with a total of heart transplants completed.994Example, Comparison2022Annual Increase269Example. Although the number of heart transplant surgeries is increasing, the gap remains large compared to the number of new heart failure patients each year.

In recent years, cardiac surgery has developed rapidly, with an increasing number of open-heart surgeries and improving surgical outcomes. However, some patients still require mechanical circulatory support devices for cardiac assistance.2024Global Ventricular Assist Device Industry Market Size Approximately22Billion USD, compared to2023Year-over-Year Growth2billion dollars. With the continuous expansion of the global patient population suffering from cardiovascular diseases such as hypertension, ventricular septal defect, heart failure, and stroke, the market size of the global ventricular assist device industry will maintain growth.

With the continuous advancement of technological innovationVDAAdvances in Implant Surgery. In recent years, in ChinaVDAThe number of implant surgeries and hospitals performing implant surgeries is increasing. According to statistics, as of2023Year3Month, China completed domestic production4The Artificial Heart Already Applied for ListingVDATotal Implantations363Example, involving70Home Hospital.